Thursday 7 May, 2026
Introduction/Objectives: More than 50% of women take at least one medication during lactation. However, 54% of the drugs in the…
Read morePoster: Methodology - Study Design
PK/PD-INTEGRATED BAYESIAN PLATFORM DESIGN FOR PHASE II REGIMEN OPTIMISATION
Thursday 7 May, 2026
Introduction: Early-phase dose-finding generally focuses on toxicity, but new approaches are shifting to a more comprehensive quantification of benefit-risks including…
Read moreTranslational pharmacology and optimisation of a first-time-in-children protocol for the evaluation of the safety, tolerability, pharmacokinetics and preliminary efficacy of BGA002 in refractory MYCN-altered tumours.
Thursday 7 May, 2026
Introduction MYCN is a key oncogenic driver in several paediatric malignancies, including neuroblastoma, where its amplification is associated with rapid…
Read moreCROSS-PRODUCT POPULATION PHARMACOKINETIC MODELING OF HAEMOGLOBIN S POLYMERIZATION INHIBITORS TO OPTIMISE PAEDIATRIC PK STUDY DESIGN USING STOCHASTIC SIMULATION-ESTIMATION
Thursday 7 May, 2026
Objectives Conducting pharmacokinetic (PK) studies in paediatric populations presents significant challenges due to physiological vulnerability, sampling limitations [1] and ethical…
Read moreEvaluation of the Impact of Machine-learning-informed Optimal Study Design on the Identifiability of Key Pharmacokinetic Parameters in Preclinical Intravenous Rat Pharmacokinetic Studies
Thursday 7 May, 2026
Introduction: Preclinical pharmacokinetic (PK) studies for new drug candidates are typically designed empirically and in a compound agnostic manner. Optimal experimental…
Read moreOPTIMISING SAMPLING DESIGN TO ENHANCE PHARMACOKINETIC EVALUATION OF COLISTIN IN NEONATES
Thursday 7 May, 2026
Background and Objectives: Gram-negative bacteria (GNB) is the most common cause of early onset sepsis (53%) and late onset neonatal…
Read moreModel‑Informed Strategies for Methocarbamol Multi‑Particulate Regimen Development: Linking Mechanistic Modelling to Formulation Design Space
Thursday 7 May, 2026
Objectives: Methocarbamol is a skeletal muscle relaxant that acts by inhibiting polysynaptic reflexes in the spinal cord and subcortical areas….
Read moreModel-Informed Design of Interim Analysis for a PK Bridging Study and Optimization of Its Operating Characteristics
Thursday 7 May, 2026
Introduction PK bridging studies are routinely conducted to extrapolate efficacy from one population in which efficacy has been established (reference…
Read moreMAKING SPARSE DATA INFORMATIVE: POPULATION PHARMACOKINETICS AND D-OPTIMAL DESIGN FOR ORAL CIPROFLOXACIN IN ADULTS ≥75 YEARS
Thursday 7 May, 2026
Objectives: Oral ciprofloxacin remains one of the few available oral agents with activity against Pseudomonas aeruginosa. However, exposure in older…
Read moreDesign Evaluation and Optimisation with Discrete Covariates and Inter-Occasion Variability in Nonlinear Mixed Effects Models: The R Package PFIM 7.1
Thursday 7 May, 2026
Objectives Several packages for design evaluation and optimisation in pharmacometrics are based on the Fisher Information Matrix (FIM). The were…
Read more